dc.date.accessioned | 2019-08-08T15:23:45Z | |
dc.date.available | 2019-08-08T15:23:45Z | |
dc.date.created | 2019-08-08T15:23:45Z | |
dc.date.issued | 2019 | |
dc.identifier | https://hdl.handle.net/20.500.12866/7134 | |
dc.identifier | https://doi.org/10.1002/cpt.1598 | |
dc.description.abstract | We present the distribution of CYP2D6, CYP2C9 and CYP2C19 variants and predicted phenotypes in 33 native and admixed populations from Ibero-America (n>6,000) in the context of genetic ancestry (n=3,387). Continental ancestries are the major determinants of frequencies of the increased-activity allele CYP2C19*17 and CYP2C19 gUMs (negatively associated with Native American ancestry), decreased-activity alleles CYP2D6*41 and CYP2C9*2 (positively associated with European ancestry), and decreased-activity alleles CYP2D6*17 and CYP2D6*29 (positively associated with African ancestry). For the rare alleles CYP2C9*2 and CYPC19*17, European admixture accounts for their presence in Native American populations, but rare alleles CYP2D6*5 (null-activity), CYP2D6-multiplication alleles (increased activity) and CYP2C9*3 (decreased-activity) were present in the pre-Columbian Americas. The study of a broad spectrum of Native American populations from different ethno-linguistic groups shows how autochthonous diversity shaped the distribution of pharmaco-alleles and give insights on the prevalence of clinically relevant phenotypes associated with drugs such as paroxetine, tamoxifen, warfarin and clopidogrel. | |
dc.language | eng | |
dc.publisher | Wiley | |
dc.relation | Clinical Pharmacology and Therapeutics | |
dc.relation | 1532-6535 | |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.subject | Ancestry | |
dc.subject | Pharmacogenetics | |
dc.subject | Native American | |
dc.subject | CYP | |
dc.subject | Latin American | |
dc.title | Genomic ancestry, CYP2D6, CYP2C9 and CYP2C19 among Latin-Americans | |
dc.type | info:eu-repo/semantics/article | |